Two NHLBI studies confirm finding of gene in primary pulmonary hypertension

Two separate groups of scientists funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health have simultaneously identified a genetic mutation associated with primary pulmonary hypertension (PPH), a rare but devastating lung disease.

The two groups, the International PPH Consortium (investigators from Vanderbilt University, Nashville; Children's Hospital Medical Center, Cincinnati; Indiana University School of Medicine, Indianapolis; and the University of Leicester, UK.) and Columbia University investigators, independently reported that defects in the BMPR2 gene, which regulates growth and development of the lung, are associated with PPH. The defects in the gene lead to the abnormal proliferation of cells in the lung characteristic of PPH.

Although both studies suggest that only one gene is involved in PPH, neither group identified the defects in BMPR2 as the sole cause of PPH. In addition, since many people without a known family history of PPH get the disease, both groups suggested that other factors may interfere with control of tissue growth.

One report was released today on the Web site of Nature Genetics, http://press.nature.com/index2.html. The other report was released on July 20th on the Web site of the American Journal of Human Genetics, http://www.ajhg.org.

Said NHLBI Director Dr. Claude Lenfant, "This research is the culmination of nearly 20 years of work to identify possible immunologic and genetic factors in the cause and progression of PPH. Now that we have pinpointed a gene, we can focus on learning how it works. That information should enable us to devise better treatments and perhaps eventually a preventive therapy or cure."

PPH is a rare lung disease characterized by uncontrolled proliferation of cells in the blood vessels in the lungs. This build-up of cells leads to blockag

Contact: NHLBI Communications Office
NIH/National Heart, Lung, and Blood Institute

Page: 1 2

Related biology news :

1. NHLBI awards $68 million to fund clinical centers in pediatric heart disease
2. NHLBI study finds improved heart failure survival
3. NHLBI launches innovative proteomics centers
4. NHLBI study finds DASH diet and reduced sodium lowers blood pressure for all
5. NHLBI supported study finds inhaled steroids accelerate bone loss in women with asthma -- treatment still recommended for persistent asthma
6. NHLBI unveils new resources to help consumers control their blood pressure
7. NHLBI study shows reduced fat intake to lower cholesterol is safe and beneficial for children
8. Reducing sodium leads to substantial drop in blood pressure, finds NHLBI study
9. NHLBI launches genomic applications initiative -- $37 million awarded in initial effort
10. NHLBI study shows large blood pressure benefit from reduced dietary sodium
11. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies

Post Your Comments:

(Date:6/5/2020)... ... ... “Although we are disappointed to have to make this decision our primary ... We remain committed to creating a global platform to showcase the science, and ... of WMIS. , The abstract deadline for the virtual meeting is ...
(Date:6/2/2020)... ... June 02, 2020 , ... ... barcode and RFID labeling software developer and solutions provider, today reported that ... improved labeling accuracy and compliance by 100%, resulting in greater efficiency for ...
(Date:5/28/2020)... (PRWEB) , ... May 27, 2020 , ... CrucialTrak, a ... partner with New Jersey-based Critical Environments Group (CEG) to market and sell its complete ... of data center and IT environment infrastructure optimization solutions . , Brett ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... ... (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical ... team led by Dr MA has been using the zebrafish model to investigate ...
(Date:7/7/2020)... ... 06, 2020 , ... R3 International is now offering stem cell therapy for ... cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or with ... form of Alzheimers dementia, and the incidence continues to increase as individuals live longer. ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... growth of 40% in 2020, despite many obstacles created as a result of ... increase revenue for its partnered medical practices and medical manufacturers by expanding access ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... launch of a new clinical diagnostics immuno-oncology service, TissueInsight . TissueInsight ... , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists ...
Breaking Biology Technology:
Cached News: